文献速递腹部技术与安全CT

新辅助FOLFIRINOX化疗后临界可切除和局部晚期胰腺腺癌的CT评估

CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
PubMed 文献 · Eur Radiol · 2016-11-28

回顾性纳入36例新辅助FOLFIRINOX化疗(±放化疗)后二次切除的临界可切除/局部晚期胰腺腺癌患者,两位放射科医生共识阅片基线及术前CT。结果显示肿瘤最大径及三轴乘积(P3A)显著减小,但CT分期不能预测可切除性及病理缓解。

要点

  • 新辅助FOLFIRINOX(±放化疗)后CT上肿瘤最大径及P3A显著减小(P<0.0001)。
  • 即使NCCN分类稳定不变,临界可切除/局部晚期胰腺腺癌仍可能实现R0切除。
  • CT不能准确预测R0切除或病理完全缓解(ypT0N0),血管侵犯程度的减轻亦不能预测。

核心结论

  • 在新辅助FOLFIRINOX方案(±放化疗)治疗后,临界可切除/局部晚期胰腺腺癌在CT上可见显著的肿瘤体积缩小,但CT分期不能预测可切除性及病理缓解。

研究设计与样本

  • 回顾性纳入36例新辅助FOLFIRINOX化疗(±放化疗)后二次切除的临界可切除/局部晚期胰腺腺癌患者,两位放射科医生共识阅片基线及术前CT,参考标准为病理缓解及切除状态。

关键影像表现/征象

  • 治疗后肿瘤最大径及三轴乘积(P3A)均减小(P<0.0001)。
  • 仅6例根据NCCN分类出现降期,但31例实现R0切除。
  • 2例(5%)出现血管侵犯进展,并与更短的无病生存期(DFS)相关。

诊断标准与关键数值

  • 采用NCCN分类评估可切除性,并测量肿瘤最大径及三轴乘积(P3A)。
  • R0切除组术前最大径及P3A更小(P=0.019/P=0.021)。
  • 病理完全缓解组最大径及P3A变化幅度更大(P=0.011/P=0.016)。
  • 血管侵犯程度减轻不能预测R0切除或ypT0N0(P>0.05)。

临床应用与阅片要点

  • 阅片时应测量并报告肿瘤最大径及三轴乘积(P3A)的变化,因其在R0切除及病理完全缓解组中表现不同。
  • NCCN分类降期并不常见,分类稳定不能排除R0切除的可能。
  • 血管侵犯程度减轻不能作为R0切除或病理完全缓解的可靠预测指标。
  • 血管侵犯进展与更短的无病生存期(DFS)相关,需在报告中关注。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To assess anatomic changes on computed tomography (CT) after neoadjuvant FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) chemotherapy for secondary resected borderline resectable (BR) and locally advanced (LA) pancreatic adenocarcinoma and their accuracy to predict resectability and pathological response.

METHODS: Thirty-six patients with secondary resected BR/LA pancreatic adenocarcinoma after neoadjuvant FOLFIRINOX chemotherapy (± chemoradiotherapy) were retrospectively included. Two radiologists reviewed baseline and pre-surgical CTs in consensus. NCCN (National Comprehensive Cancer Network) classification, largest axis, product of the three axes (P3A), and arterial/venous involvement were studied and compared to pathological response and resection status and to disease-free survival (DFS).

RESULTS: Thirty-one patients had R0 resection, including only six exhibiting a downstaging according to the NCCN classification. After treatment, the largest axis and P3A decreased (P < 0.0001). The pre-surgical largest axis and P3A were smaller in case of R0 resection (P = 0.019/P = 0.021). The largest axis/P3A variations were higher in case of complete pathological response (P = 0.011/P = 0.016). A decrease of the arterial/venous involvement was not able to predict R0 or ypT0N0 (P > 0.05). Progression of the vascular involvement was seen in two (5 %) patients and led to a shorter DFS.

CONCLUSION: In BR/LA pancreatic adenocarcinoma after the neoadjuvant FOLFIRINOX regimen (± chemoradiotherapy), significant tumour size decreases were observed on CT. However, CT staging was not predictive of resectability and pathological response.

KEY POINTS: • Significant tumour size decreases were observed on CT after FOLFIRINOX (± chemoradiotherapy). • CT is not able to predict R0 resection accurately after FOLFIRINOX (± chemoradiotherapy). • CT is not able to predict complete response accurately after FOLFIRINOX (± chemoradiotherapy). • Even with a stable NCCN classification, BR/LA pancreatic adenocarcinoma could have R0 resection.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 2016. PMID: 27896469. doi:10.1007/s00330-016-4632-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。